ClinicalTrials.gg
CompletedNCT00473382RIDEUpdated Apr 17, 2017Results posted

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

A Phase 3 interventional study of Ranibizumab and Sham injection in Diabetes Mellitus and Macular Edema, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies testing ranibizumab in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. Ranibizumab · Diabetes Mellitus.

Enrollment
2nd of 16
382 · median 46
Started
2007
with 1 other
Phase 3
6 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
2 of 16
Genentech, Inc.

Among the 16 studies testing ranibizumab in Diabetes Mellitus, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 3, and was the 2nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 16 studies testing ranibizumab in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ranibizumab in Diabetes Mellitus, or all of them as a file.
02

Study summary

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement (CSME-CI) secondary to diabetes mellitus (Type 1 or 2). This study is identical in design to study NCT00473330 (Protocol ID FVF4170g).

The open-label extension phase of the study was stopped after receiving FDA approval of the study drug (ranibizumab) for diabetic macular edema.

Read the detailed description

This study is composed of 3 phases: (1) A 24-month controlled treatment period (monthly treatment with ranibizumab 0.3 mg, ranibizumab 0.5 mg, or sham injection) followed by (2) a 12-month treatment period in which patients randomized to the sham group who had not discontinued from treatment (still masked) could choose to receive monthly ranibizumab 0.5 mg while the 2 ranibizumab treatment groups continued on the same treatment they received in the first 2 years. Patients who had not discontinued treatment by Month 36 were eligible to continue treatment with ranibizumab 0.5 mg as needed (pro re nata, PRN) in (3) an extension phase of the study for up to 2 more years, resulting in up to 5 years possible total treatment time for some patients.

As per the protocol, Genentech terminated the study approximately 30 days after approval of ranibizumab for diabetic macular edema in the United States.

03

Conditions studied

  • Diabetes Mellitus
  • Macular Edema

Keywords

  • Lucentis
  • DME
  • Diabetes
  • Vision loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide written and, at U.S. sites, Health Insurance Portability and Accountability Act (HIPAA) authorization, and in other countries, as applicable according to national laws.
  • Age ≥ 18 years.
  • Diabetes mellitus (Type 1 or 2) .
  • Retinal thickening secondary to diabetes mellitus (DME) involving the center of the fovea with central macular thickness ≥ 275 µm in the center subfield as assessed on optical coherence tomography (OCT).
  • Best corrected visual acuity (BCVA) score in the study eye of 20/40 to 20/320 approximate Snellen equivalent using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at an initial testing distance of 4 meters.
  • Decrease in vision determined to be primarily the result of DME and not to other causes.
  • For sexually active women of , use of an appropriate form of (or abstinence) for the duration of the study.
  • Ability (in the opinion of the investigator) and willingness to return for all scheduled visits and assessments.

Exclusion criteria

Exclusion Criteria:

  • History of vitreoretinal surgery in the study eye.
  • Panretinal photocoagulation (PRP) or macular laser photocoagulation in the study eye within 3 months of screening.
  • Previous use of intraocular in the study eye (eg, triamcinolone acetonide [TA]) within 3 months of screening.
  • Previous treatment with anti-angiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of the Day 0 (first day of treatment) visit.
  • Proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR.
  • Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in the study eye.

Concurrent Ocular Conditions

  • Vitreomacular traction or epiretinal membrane in the study eye.
  • Ocular inflammation (including trace or above) in the study eye.
  • History of idiopathic or uveitis in either eye.
  • Structural damage to the center of the macula in the study eye that is likely to preclude improvement in VA following the resolution of macular edema, including atrophy of the retinal pigment epithelium (RPE), subretinal fibrosis, or organized hard-exudate plaque.
  • Ocular disorders in the study eye that may confound interpretation of study results, including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization (CNV) of any cause (eg, age-related macular degeneration (AMD), ocular histoplasmosis, or pathologic myopia).
  • Concurrent disease in the study eye that would compromise visual acuity or require medical or surgical intervention during the study period.
  • Cataract surgery in the study eye within 3 months, yttrium-aluminum-garnet (YAG) laser capsulotomy within the past 2 months, or any other intraocular surgery within the 90 days preceding Day 0.
  • Aphakia or absence of the posterior capsule in the study eye.
  • Uncontrolled glaucoma or previous filtration surgery in the study eye.
  • Spherical equivalent of the refractive error in the study eye of more than -8 diopters myopia.
  • Evidence at examination of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye or current treatment for serious systemic infection.
  • Uncontrolled blood pressure.
  • History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
  • Uncontrolled diabetes mellitus.
  • Renal failure requiring dialysis or renal transplant.
  • Participation in an trial within 30 days prior to screening that involved treatment with any drug (excluding vitamins and minerals) or device.
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or renders the subject at high risk from treatment complications.
  • Pregnancy or lactation.
  • History of allergy to fluorescein.
  • History of allergy to ranibizumab injection or related molecule.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
382 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.3 mg

    Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.5 mg

    Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.

    Drug: Ranibizumab

  • Sham comparator
    Sham injection/ranibizumab 0.5 mg

    Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.

    Drug: Sham injection

Interventions

  • Sterile solution for intravitreal injection.

    Also known as: Lucentis

  • DrugSham injection
06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Baseline to Month 24

Secondary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24, 36, and 48

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

    Time frame: Baseline to Month 48

  2. Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Months 24, 36, and 48

    VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.

    Time frame: Months 24, 36, and 48

  3. Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 24, 36, and 48

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Baseline to Month 48

  4. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36 in Patients With Focal Edema at Baseline

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

    Time frame: Baseline to Month 36

  5. Mean Change From Baseline in Central Foveal Thickness at Months 24, 36, and 48

    Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

    Time frame: Baseline to Month 48

  6. Percentage of Patients With a ≥ 3-step Worsening From Baseline in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale Score for Eyes at Months 24 and 36

    The severity of diabetic retinopathy was graded on a 10-point scale by the central reading center by comparing patient fundus photographic images with a set of standard images. 1=diabetic retinopathy (DR) severity level 10, 12 (DR absent), 2=DR severity level 14A-14C, 14Z, 15, 20 (DR questionable, microaneurysms only), 3=DR severity level 35A-35F (mild non-proliferative \[NP\]DR), 4=DR severity level 43A, 43B (moderate NPDR), 5=DR severity level 47A-47D (moderately severe NPDR), 6=DR severity level 53A-53E (severe NPDR), 7=DR severity level 60, 61A, 61B (mild proliferative \[P\]DR), 8=DR severity level 65A-65C (moderate PDR), 9=DR severity level 71A-71D (high-risk PDR), 10=DR severity level 90 (cannot grade). A lower score indicates less severe diabetic retinopathy.

    Time frame: Baseline to Month 36

  7. Percentage of Patients With Resolution of Leakage at Month 24

    Resolution of leakage was defined as total area of fluorescein leakage in the central, inner, and outer subfields of the 0 Disc Area. Leakage was assessed in fluorescein angiographic images by the central reading center.

    Time frame: Baseline to Month 24

  8. Mean Number of Macular Laser Treatments From Baseline Through Months 24 and 36

    The need for macular laser treatment was evaluated by the masked (evaluating) physician. Macular laser was administered per protocol-specified objective and subjective criteria starting at Month 3.

    Time frame: Baseline to Month 36

  9. Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 36 and 48

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Baseline to Month 48

  10. Mean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

    Time frame: Month 36 to Month 48

  11. Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 48

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Month 36 to Month 48

  12. Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48

    Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

    Time frame: Month 36 to Month 48

07

Results

Posted Jan 17, 2013

Participant flow

Patients were recruited from study sites in the United States, Argentina, Peru, Columbia, Chile, and Peru. There were 47 patients from the Latin American countries.

Core Study
Participant flow — Core Study
MilestoneSham Injection/Ranibizumab 0.5 mgRanibizumab 0.3 mgRanibizumab 0.5 mg
Started130125127
Completed1029898
Not completed282729
Withdrew: Adverse event311
Withdrew: Death3510
Withdrew: Lost to follow-up333
Withdrew: Physician decision122
Withdrew: Subject non-compliance521
Withdrew: Subject needed other treatment132
Withdrew: Subject's decision121110
Open-label Extension Through Month 48
Participant flow — Open-label Extension Through Month 48
MilestoneSham Injection/Ranibizumab 0.5 mgRanibizumab 0.3 mgRanibizumab 0.5 mg
Started888384
Completed384237
Not completed504147
Withdrew: Adverse event001
Withdrew: Death133
Withdrew: Lost to follow-up121
Withdrew: Subject's decision516
Withdrew: Sponsor's decision to terminate study413436
Withdrew: Subject required other intervention210
Open-label Extension Through Month 60
Participant flow — Open-label Extension Through Month 60
MilestoneSham Injection/Ranibizumab 0.5 mgRanibizumab 0.3 mgRanibizumab 0.5 mg
Started888384
Completed212
Not completed868282
Withdrew: Adverse event002
Withdrew: Death174
Withdrew: Lost to follow-up131
Withdrew: Subject's decision716
Withdrew: Sponsor's decision to terminate study757069
Withdrew: Subject required other intervention210

Outcome measures

PrimaryPercentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Baseline to Month 24
Reported as:
Number · Percentage of patients
Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 2433.6 (25.3 to 41.9)45.7 (37.0 to 54.3)12.3 (6.7 to 18.0)
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.0001 (An adjustment was made for multiple treatment comparisons of the ranibizumab dose groups with the control group.) · Difference in percentage at month 24: 20.8 · 95% CI 11.4 to 30.2The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.0001 (An adjustment was made for multiple treatment comparisons of the ranibizumab dose groups with the control group.) · Difference in percentage at month 24: 33.3 · 95% CI 23.8 to 42.8The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24, 36, and 48

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

Time frame:
Baseline to Month 48
Reported as:
Mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24, 36, and 48
LettersRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 2410.9 ± 10.412.0 ± 14.92.3 ± 14.2NA ± NA
Month 3610.6 ± 12.911.4 ± 16.3NA ± NA4.7 ± 13.3
Month 48 (n=34,39,39,0)11.1 ± 12.012.4 ± 9.7NA ± NA4.6 ± 12.8
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · ANOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): 8.5 · 95% CI 5.4 to 11.5The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
  • Ranibizumab 0.5 mg vs Sham Injection · ANOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): 9.9 · 95% CI 6.4 to 13.3The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
SecondaryPercentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Months 24, 36, and 48

VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.

Time frame:
Months 24, 36, and 48
Reported as:
Number · Percentage of patients
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Months 24, 36, and 48
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 2454.4 (45.7 to 63.1)62.2 (53.8 to 70.6)34.6 (26.4 to 42.8)NA (NA to NA)
Month 3655.2 (46.5 to 63.9)59.1 (50.5 to 67.6)NA (NA to NA)42.3 (33.8 to 50.8)
Month 48 (n=39,39,0,34)64.1 (47.2 to 78.8)56.4 (39.6 to 72.2)NA (NA to NA)47.1 (29.8 to 64.9)
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.0002 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 21.4 · 95% CI 10.8 to 31.9The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 27.1 · 95% CI 16.4 to 37.9The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
SecondaryPercentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 24, 36, and 48

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Baseline to Month 48
Reported as:
Number · Percentage of patients
Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 24, 36, and 48
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 2498.4 (96.2 to 100.0)96.1 (92.7 to 99.4)91.5 (86.8 to 96.3)NA (NA to NA)
Month 3696.8 (93.7 to 99.9)96.1 (92.7 to 99.4)NA (NA to NA)92.3 (87.7 to 96.9)
Month 48 (n=39,39,0,34)97.4 (86.5 to 99.9)97.4 (86.5 to 99.9)NA (NA to NA)94.1 (80.3 to 99.3)
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.0119 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 7.1 · 95% CI 1.7 to 12.6The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.1384 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 4.5 · 95% CI -1.2 to 10.1The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36 in Patients With Focal Edema at Baseline

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

Time frame:
Baseline to Month 36
Reported as:
Mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36 in Patients With Focal Edema at Baseline
LettersRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 2410.5 ± 11.912.8 ± 11.01.9 ± 17.0NA ± NA
Month 3610.8 ± 12.110.9 ± 16.6NA ± NA6.6 ± 14.4
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · ANOVA · p = 0.0102 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): 8.3 · 95% CI 2.0 to 14.6The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
  • Ranibizumab 0.5 mg vs Sham Injection · ANOVA · p = 0.0005 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): 11.2 · 95% CI 5.1 to 17.3The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
SecondaryMean Change From Baseline in Central Foveal Thickness at Months 24, 36, and 48

Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

Time frame:
Baseline to Month 48
Reported as:
Mean · µm
Mean Change From Baseline in Central Foveal Thickness at Months 24, 36, and 48
µmRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 24-259.8 ± 169.3-270.7 ± 201.6-125.8 ± 198.3NA ± NA
Month 36-261.8 ± 180.8-266.7 ± 207.8NA ± NA-213.2 ± 193.5
Month 48 (n=38,39,0,33)-251.4 ± 173.8-291.6 ± 200.7NA ± NA-258.7 ± 182.3
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · ANCOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): -111.8 · 95% CI -151.6 to -72.0The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
  • Ranibizumab 0.5 mg vs Sham Injection · ANCOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): -132.2 · 95% CI -169.7 to -94.8The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
SecondaryPercentage of Patients With a ≥ 3-step Worsening From Baseline in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale Score for Eyes at Months 24 and 36

The severity of diabetic retinopathy was graded on a 10-point scale by the central reading center by comparing patient fundus photographic images with a set of standard images. 1=diabetic retinopathy (DR) severity level 10, 12 (DR absent), 2=DR severity level 14A-14C, 14Z, 15, 20 (DR questionable, microaneurysms only), 3=DR severity level 35A-35F (mild non-proliferative \[NP\]DR), 4=DR severity level 43A, 43B (moderate NPDR), 5=DR severity level 47A-47D (moderately severe NPDR), 6=DR severity level 53A-53E (severe NPDR), 7=DR severity level 60, 61A, 61B (mild proliferative \[P\]DR), 8=DR severity level 65A-65C (moderate PDR), 9=DR severity level 71A-71D (high-risk PDR), 10=DR severity level 90 (cannot grade). A lower score indicates less severe diabetic retinopathy.

Time frame:
Baseline to Month 36
Reported as:
Number · Percentage of patients
Percentage of Patients With a ≥ 3-step Worsening From Baseline in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale Score for Eyes at Months 24 and 36
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 241.7 (0 to 4.1)0 (0 to 0)5.6 (1.6 to 9.7)NA (NA to NA)
Month 360.9 (0 to 2.5)0.8 (0 to 2.5)NA (NA to NA)3.2 (0.1 to 6.3)
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.0853 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: -4.3 · 95% CI -9.3 to 0.8The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.0073 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: -5.8 · 95% CI -9.8 to -1.7The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
SecondaryPercentage of Patients With Resolution of Leakage at Month 24

Resolution of leakage was defined as total area of fluorescein leakage in the central, inner, and outer subfields of the 0 Disc Area. Leakage was assessed in fluorescein angiographic images by the central reading center.

Time frame:
Baseline to Month 24
Reported as:
Number · Percentage of patients
Percentage of Patients With Resolution of Leakage at Month 24
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Percentage of Patients With Resolution of Leakage at Month 2417.1 (10.4 to 23.7)30.7 (22.7 to 38.7)2.3 (0 to 4.9)
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = 0.0002 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 14.0 · 95% CI 6.8 to 21.1The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Difference in percentage at month 24: 28.3 · 95% CI 20.2 to 36.4The percentage for each group and the difference in percentage between groups were estimated using the weighted average of the observed percentages and the differences in observed percentages over the strata using the Cochran-Mantel-Haenszel weights.
SecondaryMean Number of Macular Laser Treatments From Baseline Through Months 24 and 36

The need for macular laser treatment was evaluated by the masked (evaluating) physician. Macular laser was administered per protocol-specified objective and subjective criteria starting at Month 3.

Time frame:
Baseline to Month 36
Reported as:
Mean · Treatments
Mean Number of Macular Laser Treatments From Baseline Through Months 24 and 36
TreatmentsRanibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionSham Injection/Ranibizumab 0.5 mg
Month 240.7 ± 1.40.3 ± 0.71.6 ± 1.6NA ± NA
Month 360.9 ± 1.80.4 ± 0.9NA ± NA1.7 ± 1.6
Statistical analysis
  • Ranibizumab 0.3 mg vs Sham Injection · ANOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): -0.9 · 95% CI -1.3 to -0.5The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
  • Ranibizumab 0.5 mg vs Sham Injection · ANOVA · p = <0.0001 (To manage the type I error rate while testing multiple secondary efficacy endpoints for statistical significance, a type I error management plan was implemented. Secondary endpoints were prioritized and tested using a hierarchical testing procedure.) · Mean difference (final values): -1.3 · 95% CI -1.6 to -1.0The analysis was stratified by baseline BCVA score (≤55, \>55 letters), baseline HbA1c (≤8%, \>8%), and prior therapy for ME in the study eye (yes, no).
SecondaryPercentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 36 and 48

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Baseline to Month 48
Reported as:
Number · Percentage of patients
Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 36 and 48
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection/Ranibizumab 0.5 mg
Month 3636.8 (28.3 to 45.3)40.2 (31.6 to 48.7)19.2 (12.5 to 26.0)
Month 48 (n=39,39,34)48.7 (32.4 to 65.2)41.0 (25.6 to 57.9)17.6 (6.8 to 34.5)
SecondaryMean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

Time frame:
Month 36 to Month 48
Reported as:
Mean · Letters
Mean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48
LettersRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection/Ranibizumab 0.5 mg
Mean Change From Month 36 in Best Corrected Visual Acuity (BCVA) Score in the Study Eye at Month 48-0.9 ± 8.30.3 ± 10.7-2.6 ± 8.8
SecondaryPercentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 48

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Month 36 to Month 48
Reported as:
Number · Percentage of patients
Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 48
Percentage of patientsRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection/Ranibizumab 0.5 mg
Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score in the Study Eye From Month 36 at Month 4892.3 (79.1 to 98.4)97.4 (86.5 to 99.9)88.2 (72.5 to 96.7)
SecondaryMean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48

Central foveal thickness was assessed in optical coherence tomographic images by the central reading center. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

Time frame:
Month 36 to Month 48
Reported as:
Mean · µm
Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48
µmRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection/Ranibizumab 0.5 mg
Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 4846.1 ± 148.144.1 ± 86.39.6 ± 78.9

Adverse events

Collected over Adverse events were recorded from the first day of treatment through Month 60. The sham Months 0-36 group includes patients randomized to sham. The sham Months 0-24 group includes patients who received sham during the first 24 months of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham Injection - Months 0-24—54/127 (42.5%)123/127 (96.9%)
Sham Injection/Ranibizumab 0.5 mg - Months 0-36—68/127 (53.5%)123/127 (96.9%)
Ranibizumab 0.3 mg - Months 0-36—54/125 (43.2%)120/125 (96%)
Ranibizumab 0.5 mg - Months 0-36—67/124 (54%)121/124 (97.6%)
Sham Injection/Ranibizumab 0.5 mg - Months 37-60—19/88 (21.6%)65/88 (73.9%)
Ranibizumab 0.3 mg - Months 37-60—31/83 (37.3%)63/83 (75.9%)
Ranibizumab 0.5 mg - Months 37-60—18/84 (21.4%)62/84 (73.8%)
Most frequent serious events
Showing 10 of 239
Most frequent serious events
EventSham Injection - Months 0-24Sham Injection/Ranibizumab 0.5 mg - Months 0-36Ranibizumab 0.3 mg - Months 0-36Ranibizumab 0.5 mg - Months 0-36Sham Injection/Ranibizumab 0.5 mg - Months 37-60Ranibizumab 0.3 mg - Months 37-60Ranibizumab 0.5 mg - Months 37-60
Vitreous haemorrhage (F)Eye disorders2/1273/12710/1254/1240/880/830/84
PneumoniaInfections and infestations5/1275/1271/1258/1242/881/831/84
Myocardial infarctionCardiac disorders6/1277/1278/1253/1240/883/830/84
Cardiac failure congestiveCardiac disorders6/1277/1273/1254/1245/882/832/84
Coronary artery diseaseCardiac disorders1/1273/1272/1256/1240/882/830/84
Renal failure acuteRenal and urinary disorders2/1272/1272/1251/1241/883/831/84
Cerebrovascular accidentNervous system disorders2/1272/1273/1254/1240/882/832/84
Renal failureRenal and urinary disorders3/1274/1273/1254/1241/881/831/84
Acute myocardial infarctionCardiac disorders0/1272/1274/1251/1240/881/831/84
Vitreous haemorrhage (S)Eye disorders3/1274/1271/1250/1240/881/831/84
Most frequent other events
Showing 10 of 81
Most frequent other events
EventSham Injection - Months 0-24Sham Injection/Ranibizumab 0.5 mg - Months 0-36Ranibizumab 0.3 mg - Months 0-36Ranibizumab 0.5 mg - Months 0-36Sham Injection/Ranibizumab 0.5 mg - Months 37-60Ranibizumab 0.3 mg - Months 37-60Ranibizumab 0.5 mg - Months 37-60
Conjunctival haemorrhage (S)Eye disorders40/12745/12754/12563/1247/884/836/84
Macular oedema (F)Eye disorders28/12737/12746/12553/12410/888/839/84
Cataract (F)Eye disorders29/12732/12738/12541/1245/881/833/84
Retinal haemorrhage (F)Eye disorders20/12731/12732/12540/1246/889/838/84
Cataract (S)Eye disorders35/12739/12731/12535/1245/886/835/84
HypertensionVascular disorders31/12735/12733/12538/1245/883/833/84
Retinal haemorrhage (S)Eye disorders22/12726/12722/12534/1244/889/837/84
Macular oedema (S)Eye disorders26/12733/12732/12526/1249/886/839/84
Intraocular pressure increased (S)Investigations14/12717/12720/12525/1242/882/833/84
Diabetic retinal oedema (F)Eye disorders19/12720/12725/12516/1242/880/831/84

Baseline characteristics

The Baseline Characteristics of the patients enrolled in the open-label extension phase (N=88, 83, 84 patients originally randomized to the ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection groups, respectively) were similar to the Baseline Characteristics of the patients enrolled in the core study.

Age, Continuous
Age, Continuous(years)Ranibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionTotal
Mean62.7 ± 11.161.8 ± 10.163.5 ± 10.862.7 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionTotal
Female524764163
Male738066219
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gonzalez VH, Wang PW, Ruiz CQ. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done". Ophthalmology. 2021 Oct;128(10):1448-1457. doi: 10.1016/j.ophtha.2019.08.010. Epub 2019 Aug 21. PubMed 31668888 ↗
  • Wykoff CC, Eichenbaum DA, Roth DB, Hill L, Fung AE, Haskova Z. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2018 Oct;2(10):997-1009. doi: 10.1016/j.oret.2018.06.005. Epub 2018 Aug 1. PubMed 31047503 ↗
  • Sun JK, Wang PW, Taylor S, Haskova Z. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. Ophthalmology. 2019 May;126(5):712-720. doi: 10.1016/j.ophtha.2018.10.041. Epub 2018 Nov 9. PubMed 30419298 ↗
  • Reddy RK, Pieramici DJ, Gune S, Ghanekar A, Lu N, Quezada-Ruiz C, Baumal CR. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE. Ophthalmology. 2018 Oct;125(10):1568-1574. doi: 10.1016/j.ophtha.2018.04.002. Epub 2018 May 8. PubMed 29752001 ↗
  • Moshfeghi AA, Shapiro H, Lemmon LA, Gune S. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema. Ophthalmol Retina. 2018 Feb;2(2):86-90. doi: 10.1016/j.oret.2017.05.003. Epub 2017 Jul 27. PubMed 31047350 ↗
  • Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2016 Jul;123(7):1581-7. doi: 10.1016/j.ophtha.2016.03.038. Epub 2016 May 24. PubMed 27234930 ↗
  • Pieramici DJ, Wang PW, Ding B, Gune S. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE. Ophthalmology. 2016 Jun;123(6):1345-50. doi: 10.1016/j.ophtha.2016.02.007. Epub 2016 Mar 15. PubMed 26992841 ↗
  • Bressler NM, Varma R, Mitchell P, Suner IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials. JAMA Ophthalmol. 2016 Feb;134(2):160-6. doi: 10.1001/jamaophthalmol.2015.4636. PubMed 26584450 ↗
  • Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS; RIDE and RISE Research Group. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. Ophthalmology. 2015 Dec;122(12):2504-13.e1. doi: 10.1016/j.ophtha.2015.08.006. Epub 2015 Oct 9. PubMed 26452713 ↗
  • Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials. Ophthalmology. 2015 Aug;122(8):1573-9. doi: 10.1016/j.ophtha.2015.04.029. Epub 2015 Jun 4. PubMed 26050541 ↗
  • Bressler NM, Varma R, Suner IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A; RIDE and RISE Research Groups. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology. 2014 Dec;121(12):2461-72. doi: 10.1016/j.ophtha.2014.07.008. Epub 2014 Aug 20. PubMed 25148789 ↗
  • Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014 Sep;121(9):1783-9. doi: 10.1016/j.ophtha.2014.03.021. Epub 2014 Apr 24. PubMed 24768239 ↗
  • Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22. PubMed 23706949 ↗
  • Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012 Sep;130(9):1145-52. doi: 10.1001/archophthalmol.2012.1043. PubMed 22965590 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jan 2011 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2007
First posted
May 15, 2007
Start
Jun 2007
Primary completionActual
Jan 2011
CompletionActual
Sep 2012
Results first posted
Jan 17, 2013
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473382
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 15, 2007
Start date
Jun 2007
Primary completion
Jan 2011
Completion
Sep 2012
Results posted
Jan 17, 2013
Last update
Apr 17, 2017

Study contacts

Jason Ehrlich, M.D., Ph.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion